Anesiva — Algorx Pharmaceuticals — Merger or Acquisition (October 2005)
24 slides from Anesiva's merger presentation, Oct 19, 2005
Slide 1: Creating a Late-Stage Company Focused on Pain Management and Inflammation
Filed by Corgentech Inc. Pursuant to Rule 425 Under the Securities Act of 1933 And Deemed Filed Pursuant to Rule 14a-12 Under the Securities Exchange Act of 1934 Subject Company: AlgoRx Pharmaceuticals, Inc. Commission File No. of Subject Company: 000-51146 *** *** *** The following is a slide prese
Slide 2: Forward Looking Statements
FORWARD This “expect,” intended proposed materially merger; segments market contained Corgentech not 2 statement. topresentation place acceptance. approval to merger, grow “estimate,” in from identify and undue LOOKING Corgentech’s as AlgoRx results of includes and anticipated; reliance Actual such
Slide 3: Forward Looking Statements (Additional Information)
FORWARD Additional available documents Investor Corgentech, merger Corgentech Stockholders, 3 above. transaction transaction. Relations because Information filed Inc. described AlgoRx LOOKING which intends with they at involving Information was and the the above. will and to STATEMENTS email their S
Slide 4: Merger Agreement
MERGER Stock Corgentech Combined Richard John Dr. James 4 Ronald McLaughlin Transaction Huang Brewer, AGREEMENT management Burch, tonewly issue Dr. as current sufficient elected Charles CEOteam AlgoRx as Cohen, will shares president work CEO, Thomas such towith tothat integrate serve Colligan, respo
Slide 5: Deal Timeline
DEAL Both Merger S-4 Shareholder 5 and boards TIMELINE requires documents related vote have joint stockholder expected approved toProxy be filed to Statement merger approval occur imminently in late 2005 / early 2006
Slide 6: Combined Company
COMBINED Pain Sizable Unmet Cheaper 6 Management or Patient Trials Underserved COMPANY Populations and Inflammation Medical Needs Differentiated Products with Clear Advantages over Current Therapies Substantial Body of Preclinical and Clinical Data Clear Regulatory Pathways Faster,
Slide 7: Product Pipeline
PRODUCT PRECLINICAL Pre-procedural Post-surgical NF-kB Atopic ALGRX Cutaneous * 7 dermatitis Decoy Does 3268 4975 1207 neuropathic PIPELINE pain not *analgesia PHASE reflect (eczema) Morton’s pain comprehensive 1(003) PHASE neuroma Pre-procedural 2 PHASE Tendonitis list of3trials analgesia currently
Slide 8: Creating a Late-Stage Pain Company
CREATING Four Each All Phase Statistically Second Expect Development Marketing, Financial 8 discovery product drug 3product to Phase program strength file has can commercialization, significantly LATE-STAGE development NDA and 3potential unique be approval trial ALGRX commercialized commercial devel
Slide 9: ALGRX 3268 Topical Local Anesthesia
ALGRX TOPICAL Reduction Indication Two Key Sterile, Rapid Within No Ease 9 vasoconstriction desirable Phase ofonset 1pre-filled, use 3268- minute of LOCAL 3with oftrials pain product action with no needle-free associated required ANESTHESIA dressings with duration attributes good for with disposable
Slide 10: Rapid Onset of Action Critical to Adoption
Rapid Package EMLA ALGRX -Data 0 10 VAS, 1 -30 -20 3 5 10 from -20 -Time 0 10 VAS, 3 -30 10 60 ALGRXmm Onset Insert 3268 after mm Phase ofhas for Action 1 EMLA trialCritical in 272 administration, 3268 an onset adults to Adoption minutes within of Product one minute, whereas EMLA is labeled for a pr
Slide 11: ALGRX 3268 Development
ALGRX Protocol Pharmacokinetics Back Antecubital 11 2,213 of Hand Age 3268 Fossa Group Adults Children DEVELOPMENT Adults Children and Phase 1Back 183 2 1306 145 Total 38 272 Safety 2of195 Safety Evaluate Hand Safety Patients Safety and and Children and Efficacy Circulating and Efficacy Primary Effi
Slide 12: Phase 3 Pediatric Protocols
PHASE IDENTICAL U.S. Design Number 500-600 Pediatric Population Confirm Objectives Primary Assessment 12 multicenter, 3’s: endpoint of subjects efficacy, subjects subjects of PEDIATRIC PROTOCOLS pain randomized, in safety ofon each either venipuncture and study TRIALS gender tolerability double-blin
Slide 13: First Phase 3 Results
FIRST Primary Statistically 574 ALGRX Placebo Well Safety 13 patients tolerated PHASE = endpoint 3268 285 significantly at group patients six 3 RESULTS achieved U.S. = (ages 289 clinical less (p=0.007) patients 3-18) pain trialon(ages sites needle 3-18) insertion in treated group compared to placebo
Slide 14: Projected Timeline for ALGRX 3268
PROJECTED Data Clinical Reviewed Regulatory File Registration Product 14 NDA fromapproval in as second 2006 aTIMELINE drug in Phase by 2007 the 3 trial FOR FDAexpected ALGRX Analgesics within 3268 and two Acute months Care Division
Slide 15: ALGRX 4975 Overview
ALGRX Capsaicin Administered site Single provide weeks Non-opioid Only noxious with Does nerve motor Activates Blocks 15 ofC-neurons reduces not fibers skills pain to administration noxious analgesia pain 4975 months affect the Overview based important associated VR1 long-term locally –other pain VR
Slide 16: ALGRX 4975 Development
ALGRX Protocol Postsurgical Bunion Hernia Achieved Total Cholecystectomy Neuropathic Morton’s Musculoskeletal End-Stage Osteoarthritis Tendonitis 16 Ongoing Knee Repair Removal Phase 4975 Neuroma Osteoarthritis 2Replacement Pain 40of 2DEVELOPMENT Patients Magnitude 48 the Pain Surgery 2 Magnitude 24
Slide 17: Phase 2 Morton's Neuroma Results
PHASE Confirm Objectives Design U.S. ALGRX Primary Statistically Well Safety placebo 17 randomized, tolerated and 2endpoint efficacy, 4975 RESULTS: population significant group achieved double-blind, safety =MORTON’S 30 pain and patients, (p=0.0188) reduction tolerability placebo-controlled placebo
Slide 18: Patient Numbers of Pain in Seven Major Countries
PREVALANCE PATIENT Prevalence Above Source: 18 indications Datamonitor NUMBERS of osteoarthritic post-operative back HIV diabetic OFare and pain PAIN all neuropathy AIDS 208,996,000 targets INpain pain pain SEVEN of 46,610,000 75,068,000 pain 847,000 Corgentech MAJOR 13,243,000 pipeline COUNTRIES
Slide 19: 3268: Topical Anesthesia Market Dynamics
3268: TOPICAL ANESTHESIA Strong pressure Current 19 focus market on cost of dynamics MARKET pain reduction LOCAL management provide and DYNAMICS patient an including excellent through-put treatment opportunity in hospitals protocols for aFundamental and fast guidelines acting, easy market Increase t
Slide 20: Pediatric In-Hospital Market
PEDIATRIC Target Only Low Faster 20 utilization 2.1MM onset marketof IN-HOSPITAL out action, ofoftopical 18MM needleless local venipuncture MARKET anesthetics injectionprocedures and (12%promotion of pediatric in children’s willprocedures) allow hospitals significant dueand to:large penetration slow
Slide 21: ALGRX 3268 Phased Marketing Approach
ALGRX 3268: Physician Hemodialysis In-hospital 21 Offices, Adult Pediatric Centers PHASED (ER) Clinical 18M MARKETING Labs, Blood Donation APPROACHCenters
Slide 22: ALGRX 4975 US Post-Operative Pain Market
ALGRX US 50% Pain 22 post-operative in indicate hospital 4975:lack POST-OPERATIVE associated of pain adequate market: withpain $1.7 increased control PAIN billion length MARKET Patients’ Virtually of stay, post-surgical all patients longer recovery experience pain experiences times, somepoorer level
Slide 23: Post-Op Pain Drug Comparison
POST-OP ALGRX Efficacy Dosing Duration Onset Rapid Safety action large 23 nerves of Rapid Cannot Single +++ 4975 Weeks PAIN nausea, +++ inject Opioids application DRUG Hoursvomiting, nearCOMPARISON Respiratory Frequent ileus depression,
Slide 24: Why This Merger Makes Sense
WHYproduct Four Each discovery Phase Statistically Development Marketing, Financial 24 drug THIS 3 program strength and has commercialization, significantly MERGER development and development unique ALGRX commercial andmechanism flexibility MAKES less 3268 programs programs pain expertise regulatory
Algorx Pharmaceuticals — Merger or Acquisition (October 2005) on 6ix